NDC Compounded Drug 71285-0012-2 Sodium Phosphate, Monobasic, Monohydrate; Anhydrous Dextrose; Aspartic Acid; Glutamic Acid; Citric Acid Monohydrate; Trisodium Citrate Dihydrate
Solution Intracoronary
Compounded Drug Product Information
Frequently Asked Questions
What is the NDC number assigned to Microplegia (msa/msg 0.92 Molar) With Cp2d?
Microplegia (msa/msg 0.92 Molar) With Cp2d was assigned by its manufacturer with NDC product code 71285-0012. This product is a drug classified as a human compounded drug. Compounded drugs are medications created by combining or altering existing drugs to meet the specific needs of certain patients. The NDC directory only includes information about compounded drugs from facilities that choose to assign NDC numbers to their products.
Which are the NDC package codes for Microplegia (msa/msg 0.92 Molar) With Cp2d?
The NDC package code 71285-0012-2 was assigned to a 120 mL in 1 BAG of sodium phosphate, monobasic, monohydrate; anhydrous dextrose; aspartic acid; glutamic acid; citric acid monohydrate; trisodium citrate dihydrate administered intracoronary via solution.
Who manufactures this product?
Microplegia (msa/msg 0.92 Molar) With Cp2d is manufactured by an outsourced facility and labeled by Central Admixture Pharmacy Services, Inc.. All compounded drugs included in the NDC directory are classified as "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)". Outsourcing facilities are a type of drug compounding facility regulated under Section 503B of the FD&C Act could be eligible for exemptions from drug registration if they meet all the conditions specified under Section 503B.